Scienza e Tecnologia
DelveInsight Evaluates a Robust RNA Interference Pipeline as Key 85+ Pharma Companies Set Foot in the RNA Interference Space
Request a sample and discover the recent advances in RNA interference treatment @
RNA interference (RNAi) is one of several RNA silencing pathways that use small RNAs as guides for sequence-specific silencing. In C. elegans, RNAi was discovered and defined as sequence-specific mRNA degradation induced by long double-stranded RNA (dsRNA). RNA interference (RNAi) technology regulates mRNA stability and translation in nearly all human cells.
RNA interference (RNAi) is a conserved biological response to double-stranded RNA that mediates resistance to both endogenous parasitic and exogenous pathogenic nucleic acids and regulates the expression of protein-coding genes. This natural mechanism for sequence-specific gene silencing has the potential to transform experimental biology and may have significant practical applications in functional genomics, therapeutic intervention, agriculture, and other fields.
Find out more about RNA interference method @
ARO-APOC3 is a subcutaneously administered RNAi therapeutic that inhibits the production of Apolipoprotein C-III (Apoc-III), a component of triglyceride-rich lipoproteins (TRLs) such as VLDL and chylomicrons, as well as a key regulator of triglyceride metabolism. The company believes that decreasing Apoc-III hepatic production will result in decreased VLDL synthesis and assembly, improved TRL breakdown, and improved clearance of VLDL and chylomicron remnants. It is currently being researched as a possible treatment for severe hypertriglyceridemia (SHTG), familial chylomicronemia syndrome (FCS), and mixed dyslipidemia. Arrowhead's RNA interference (RNAi) therapeutic is currently in phase III testing for FCS and phase II testing for mixed dyslipidemia and SHTG.
DCR-HBVS is a GalXC RNAi therapy being developed by Roche for the treatment of chronic hepatitis B virus (HBV) infection. Chronic HBV increases the risk of developing liver failure, cancer, or cirrhosis, a condition that scars the liver permanently. DCR-HBVS has the potential to contribute to the ultimate goal of achieving a functional cure in chronic HBV patients and is currently being studied by Roche as part of Phase II clinical trial in combination with other treatment regimens to induce functional cures in patients. Furthermore, it is being tested in phase I for chronic hepatitis B.
Learn more about the emerging RNA interference pipeline therapies @
Dive deep into rich insights for drugs for RNA interference treatment; visit @
For further information on the RNA interference pipeline therapeutics, reach out @
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key global messenger RNA companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted global messenger RNA epidemiology in the 7MM, i.e., the United States , EU5 ( Germany , Spain , Italy , France , and the United Kingdom ), and Japan .
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key viral RNA polymerase inhibitor companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key global messenger RNA -based vaccines and therapeutics companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key DNA-dependent RNA polymerase inhibitor companies, including among others.
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/delveinsight-evaluates-a-robust-rna-interference-pipeline-as-key-85-pharma-companies-set-foot-in-the-rna-interference-space-301664242.html